A significantly greater proportion of HRAS-mutant cancers (48.4%) were found to have co-altered mutations along the RTK/MAPK/PI3K pathways compared to KRAS- (41.4%) and NRAS-mutant (38.4%) cancers (Figure 1C) (p<0.05 for both). Here, HRAS is linked to cancer.